Fibromyalgia: a new non-drug therapy clinically validated

Fibromyalgia: a new non-drug therapy clinically validated

A new non-drug (and French!) technological solution to fight fibromyalgia was presented last Monday at an international congress. Its use demonstrates a notable improvement in the quality of life of patients. A glimmer of hope for patients who, until now, have no treatment.

Fibromyalgia is a chronic condition characterized by persistent widespread pain and sensitivity to pressure. Added to this are chronic fatigue, sleep disorders, cognitive disorders and anxiety which quickly harm the patient’s quality of life. However, even if fibromyalgia affects 2% of French people (90% of whom are women), there is currently no authorized drug treatment to alleviate the suffering of patients.

An endorphin stimulator developed in a bracelet

But a French start-up, Remedee Labs, could well break this inevitability. She has just presented a new non-drug solution at the American College of Rheumathology (ACR) congress in San Diego (USA) last Monday. Solution that aims to improve the quality of life of people affected by fibromyalgia. The start-up has invented the first endorphin stimulator based on millimeter waves which is worn via a simple bracelet, associated with an application for better monitoring and coaching in several interviews.

8 out of 10 patients feel an improvement in their quality of life

The initial idea is good. But the results of the first studies even more. A study of this solution carried out over 6 months on 170 patients has now revealed very encouraging results.

  • 6 out of 10 patients feel a real reduction in the impact of fibromyalgia at 3 months, which is maintained at 6 months;
  • 8 out of 10 patients report an improvement in their health;
  • 1 in 3 patients say they have greatly improved their health.

With significant improvement in pain, sleep, and symptoms of depression and anxiety at the forefront.

“These results mark a key step towards our objective of obtaining medical device status in the fibromyalgia indication and the ambition to become a first-line solution for patients suffering from fibromylagia” signs the Doctor David Crouzier (PhD), co-founder and CEO of Remedee Labs.

Soon in first-line treatment?

The Remedee Labs solution therefore promises to be new hope for the community of suffering people. A hope heard by the associations:

“The non-drug therapy offered by Remedee Labs, the study of which shows very positive results, therefore represents a advanced majeure In the prise in charge of the fibromyalgia, because it offers a global approach and establishes a human connection through personalized coaching. The financial situation of fibromyalgia patients is often precarious, we hope that this therapy can quickly be covered by social security.” evaluated Nadine Randon president of the Fibromyalgia SOS association.

Now validated, the Remedee Labs solution aims to become a first-line treatment for fibromyalgia.